secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001193125-25-193450
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics receives $4.2M milestone from Dr. Reddy's for ALS IND acceptance
--------------------------------------------------------------------------------

- FDA accepted IND for COYA 302 Phase 2 study in ALS, triggering $4.2M milestone from Dr. Reddy's Laboratories.
- Additional $4.2M payment due upon first patient dosing in the Phase 2 study.
- Phase 2 trial is randomized, double-blind, placebo-controlled, 24-week with 24-week open-label extension.
- Milestone arises from Development and License Agreement signed December 5, 2023.
- Payment signals progress in clinical development for COYA 302 combination therapy in ALS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312525193450/0001193125-25-193450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312525193450/d95745d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-193450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer